| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| betiatide | Injection, powder for | 1 mg | Current | Emergency Supply Only | Manufacturing | 7/11/2025 |
| tobramycin | Injection, solution | 80 mg | Anticipated | Available | Manufacturing | 7/11/2025 |
| primidone | Tablet, uncoated | 250 mg | Current | Emergency Supply Only | Manufacturing | 7/11/2025 |
| trandolapril | Capsule | 2 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 7/11/2025 |
| topiramate | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| sodium lactate~magnesium chloride hexahydrate~glucose~sodium chloride~calcium chloride dihydrate | Solution, irrigation | 4.48 g/L~50.8 mg/L~15 g/L~5.38 g/L~183 mg/L | Resolved | Available | Manufacturing | 7/11/2025 |
| glucose~sodium chloride~sodium lactate~magnesium chloride hexahydrate~calcium chloride dihydrate | Solution, irrigation | 25 g/L~5.38 g/L~4.48 g/L~50.8 mg/L~183 mg/L | Resolved | Available | Manufacturing | 7/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 4.986 mg | Anticipated | Available | Manufacturing | 7/11/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.38 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| sumatriptan succinate | Tablet, film coated | 69.99 mg | Current | Limited Availability | Manufacturing | 7/11/2025 |
| phenobarbital | Tablet, uncoated | 30 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 27 mg~200 mg~100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 7/11/2025 |
| levodopa~carbidopa monohydrate~entacapone | Tablet, film coated | 150 mg~40.5 mg~200 mg | Current | Unavailable | Unexpected increase in consumer demand | 7/11/2025 |
| levodopa~carbidopa monohydrate~entacapone | Tablet, film coated | 200 mg~54.1 mg~200 mg | Current | Limited Availability | Unexpected increase in consumer demand | 7/11/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 7/11/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 7/11/2025 |
| mebeverine hydrochloride | Tablet, film coated | 135 mg | Current | Limited Availability | Manufacturing | 7/11/2025 |
| latanoprost | Eye Drops, solution | .05 mg/mL | Anticipated | Available | Manufacturing | 7/11/2025 |
| metaraminol tartrate | Injection, solution | 19 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 7/11/2025 |
| aprepitant | Capsule | 165 mg | Anticipated | Available | Manufacturing | 7/11/2025 |
| fingolimod hydrochloride | Capsule | 560 microgram | Anticipated | Available | Manufacturing | 7/11/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| valsartan~sacubitril | Tablet, film coated | 51.4 mg~48.6 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| sacubitril~valsartan | Tablet, film coated | 24.3 mg~25.7 mg | Current | Unavailable | Manufacturing | 7/11/2025 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, modified release | 56.685 mg~1000 mg | Current | Limited Availability | Manufacturing | 7/11/2025 |
| nitrofurantoin | Capsule, hard | 50 mg | Anticipated | Available | Manufacturing | 7/11/2025 |
| naltrexone hydrochloride | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 7/11/2025 |
| rivaroxaban | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 7/11/2025 |
| carbidopa monohydrate~levodopa | Tablet, uncoated | 26.9 mg~100 mg | Resolved | Available | Manufacturing | 7/11/2025 |
| bumetanide | Tablet, uncoated | 1 mg | Current | Limited Availability | Manufacturing | 7/11/2025 |
| diltiazem hydrochloride | Capsule, modified release | 360 mg | Current | Limited Availability | Manufacturing | 7/11/2025 |
| magnesium chloride hexahydrate~calcium chloride dihydrate~sodium lactate~sodium chloride~icodextrin | Solution, dialysis | 51 mg/L~257 mg/L~4.5 g/L~5.4 g/L~75 g/L | Resolved | Available | Manufacturing | 7/11/2025 |
| nizatidine | Capsule, hard | 300 mg | Anticipated | Available | Manufacturing | 7/11/2025 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 20.51 mg~16 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 7/11/2025 |
| lamotrigine | Tablet, dispersible | 200 mg | Current | Limited Availability | Manufacturing | 7/11/2025 |
| sodium amidotrizoate~amidotrizoate meglumine | Oral Liquid, solution | 100 mg/mL~660 mg/mL | Discontinued | Unavailable | Seasonal depletion of stock | 6/11/2025 |
| live varicella vaccine | Injection, powder for | 2700 PFU/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 6/11/2025 |
| minoxidil | Tablet, uncoated | 10 mg | Anticipated | Available | Manufacturing | 6/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 75 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 6/11/2025 |
| Infliximab | Injection, powder for | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 6/11/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 6/11/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 6/11/2025 |
| verapamil hydrochloride | Tablet, modified release | 240 mg | Current | Limited Availability | Manufacturing | 5/11/2025 |
| terbutaline sulfate | Injection, solution | .5 mg/mL | Anticipated | Available | Manufacturing | 5/11/2025 |
| midazolam | Injection, solution | 5 mg/mL | Resolved | Available | Manufacturing | 5/11/2025 |
| pantoprazole sodium sesquihydrate | Tablet, enteric coated | 45.4 mg | Resolved | Available | Unexpected increase in consumer demand | 5/11/2025 |
| Alteplase | Injection, powder for | 50 mg | Current | Limited Availability | Unexpected increase in consumer demand | 5/11/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Resolved | Available | Manufacturing | 5/11/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 5/11/2025 |
| amlodipine besilate~atorvastatin calcium trihydrate | Tablet, film coated | 13.88 mg~10.844 mg | Current | Unavailable | Manufacturing | 5/11/2025 |
| mesalazine | Granules, modified release | 4 g | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 5/11/2025 |
| dabigatran etexilate mesilate | Capsule, hard | 172.95 mg | Current | Unavailable | Manufacturing | 5/11/2025 |
| doxepin hydrochloride | Capsule, hard | 11.3 mg | Anticipated | Available | Manufacturing | 5/11/2025 |
| midodrine hydrochloride | Tablet | 5 mg | Current | Unavailable | Manufacturing | 5/11/2025 |
| larotrectinib sulfate | Capsule, hard | 30.7 mg | Resolved | Available | Unexpected increase in consumer demand | 5/11/2025 |
| tenofovir disoproxil succinate~emtricitabine | Tablet, film coated | 300.6 mg~200 mg | Current | Unavailable | Manufacturing | 5/11/2025 |
| flecainide acetate | Tablet | 50 mg | Current | Unavailable | Manufacturing | 5/11/2025 |
| rivaroxaban | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 5/11/2025 |
| rivaroxaban | Tablet, film coated | 15 mg | Anticipated | Available | Manufacturing | 5/11/2025 |
| furosemide | Injection, solution | 20 mg | Resolved | Available | Manufacturing | 5/11/2025 |
| ethinylestradiol~norethisterone | Tablet, uncoated | 36 microgram~500 microgram | Current | Limited Availability | Manufacturing | 5/11/2025 |
| Alteplase | Diluent, not applicable | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 5/11/2025 |
| fluorouracil | Injection, solution | 50 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 5/11/2025 |
| flunitrazepam | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 5/11/2025 |
| indometacin | Suppository, moulded | 100 mg | Current | Unavailable | Manufacturing | 4/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 10 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 4/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 4/11/2025 |
| alfentanil hydrochloride | Injection, solution | 1.0876 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 4/11/2025 |
| nystatin | Oral Liquid, suspension | 100000 IU/mL | Current | Unavailable | Unexpected increase in consumer demand | 4/11/2025 |
| pregabalin | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 4/11/2025 |
| escitalopram oxalate | Tablet, film coated | 12.74 mg | Current | Unavailable | Commercial Changes / Commercial viability | 4/11/2025 |
| escitalopram oxalate | Tablet, film coated | 25.47 mg | Current | Limited Availability | Manufacturing | 4/11/2025 |
| lacosamide | Tablet, film coated | 150 mg | Current | Limited Availability | Manufacturing | 4/11/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Unavailable | Manufacturing | 4/11/2025 |
| levothyroxine sodium | Tablet, uncoated | .05 mg | Current | Limited Availability | Manufacturing | 4/11/2025 |
| ramipril | Tablet, uncoated | 1.25 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 4/11/2025 |
| ramipril | Tablet, uncoated | 2.5 mg | Current | Limited Availability | Manufacturing | 4/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Limited Availability | Manufacturing | 4/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Unavailable | Manufacturing | 4/11/2025 |
| sertraline hydrochloride | Tablet, film coated | 55.96 mg | Current | Unavailable | Manufacturing | 3/11/2025 |
| clozapine | Oral Liquid, suspension | 50 mg/mL | Current | Unavailable | Manufacturing | 3/11/2025 |
| risperidone | Tablet | 1 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 3/11/2025 |
| lamivudine | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| olanzapine | Tablet, orally disintegrating | 10 mg | Resolved | Available | Manufacturing | 3/11/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 3/11/2025 |
| finasteride | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 3/11/2025 |
| risperidone | Tablet, film coated | .5 mg | Resolved | Available | Manufacturing | 3/11/2025 |
| entecavir | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| primaquine phosphate | Tablet, uncoated | 13.2 mg | Current | Emergency Supply Only | Manufacturing | 3/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| nicorandil | Tablet, uncoated | 20 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Anticipated | Available | Manufacturing | 3/11/2025 |
| phenytoin sodium | Capsule, hard | 30 mg | Resolved | Available | Manufacturing | 3/11/2025 |
| bendamustine hydrochloride | Injection, powder for | 25 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 3/11/2025 |
| finasteride | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| Tocilizumab | Injection, solution | 162 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| bleomycin sulfate | Injection, powder for | 15000 IU | Anticipated | Available | Manufacturing | 3/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | 1 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | .125 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/11/2025 |
2025年11月10日